Nov 13 (Reuters) - Laboratorio Reig Jofre SA RJFE.MC :
* 9-MONTH NET PROFIT 5.3 MILLION EUROS VERSUS 2.3 MILLION
EUROS
YEAR AGO
* 9-MONTH EBITDA 19.2 MILLION EUROS VERSUS 12.4 MILLION
EUROS YEAR
AGO
* 9-MONTH TURNOVER 170.4 MILLION EUROS VERSUS 147.1 MILLION
EUROS
YEAR AGO
* SAYS IMPACTS IN 2020 DERIVED FROM COVID-19 WILL PROBABLY
RESULT
IN A SLIGHT DROP IN SALES
* SAYS PRODUCTION OF ESSENTIAL DRUGS RELATED TO COVID-19 MAY
AFFECT 2020 REVENUES AND RESULTS DUE TO POSTPONEMENT OF
MANUFACTURE AND SALE OF OTHER PRODUCTS
* SAYS INTEGRATION OF NEW PRODUCTS AND INTERNATIONAL GROWTH
TO
RESULT IN REVENUE GROWTH TO BE ACHIEVED IN 2020
* SAYS EXPECTS TO CLOSE 2020 WITH GROWTH IN SALES AND PROFIT
* SAYS Q4 WILL PRESENT LOWER GROWTH RATES AND REFLECT THE
IMPACTS
OF COVID-19 ON REVENUE OF SPECIALTY PHARMACARE PRODUCTS
* SAYS PHARMACEUTICAL TECHNOLOGIES DIVISION IS EXPECTED TO
REGISTER THE HIGHEST ORGANIC GROWTH IN 2020
* SAYS MODERATE REVENUE GROWTH IS EXPECTED IN CONSUMER
HEALTHCARE
Source text for Eikon: ID:nCNM6VhNwP ID:nCNM8smfZ5
Further company coverage: RJFE.MC
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))